Clinical trials: Tear Film Deficiency
Dry Eye, Dry Eye Syndromes
Tear Production by Nasal Neurostimulation Compared to Active Control
This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones…
- Conditions
- Dry Eye, Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Trial name
- NCT02970799
- Testing
- Intranasal Neurostimulator
- Volunteers
- 27 people
- Sponsor
- Oculeve, Inc.
Dry Eye Syndromes
Long Term Administration Study of OPC-12759 Ophthalmic Suspension
The purpose of this study is to evaluate safety and efficacy of OPC-12759 ophthalmic suspension during 52 weeks in dry eye patients
- Trial name
- NCT00818324
- Testing
- OPC-12759 Ophthalmic suspension
- Where
- 5 sites in Japan
- Volunteers
- 154 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dry Eye Syndrome
Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
The purpose of this study was to determine if Sodium Hyaluronate, 0.18% is effective in treating the signs and symptoms of dry eye disease.
- Trial name
- NCT01382225
- Testing
- Sodium Hyaluronate Ophthalmic Solution, 0.18%, Vehicle
- Volunteers
- 1,936 people
- Sponsor
- Alcon Research
Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
- Trial name
- SS (NCT04129164)
- Testing
- VIB4920
- Where
- 62 sites in United States, Argentina and 10 more
- Volunteers
- 183 people
- Sponsor
- Amgen
Dry Eye Syndrome, Myopia
Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens Wearers
The purpose of this study was to evaluate the reduction of contact lens-related dryness symptoms when symptomatic weekly/monthly contact lens wearers were switched to DAILIES® AquaComfort Plus® lenses for a two-week period using…
- Trial name
- NCT01614600
- Testing
- Nelfilcon A contact lenses
- Volunteers
- 88 people
- Sponsor
- Alcon Research
Keratoconjunctivitis Sicca
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
This study will evaluate the efficacy of cyclosporine ophthalmic solution vs. other non-prescription treatments in patients with dry eye disease.
- Trial name
- NCT00717418
- Testing
- cyclosporine ophthalmic emulsion 0.05%, artificial tears
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Allergan
Dry Eye Syndrome
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
- Trial name
- NCT01212471
- Testing
- Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndromes
Dose-response Study of OPC-12759 Ophthalmic Suspension
The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.
- Trial name
- NCT00234078
- Testing
- 0.5% OPC-12759, 1% OPC-12759, 2% OPC-12759
- Where
- Japan
- Volunteers
- 290 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dry Eye Syndrome
Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.
- Trial name
- NCT01163643
- Testing
- 0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, 1% BOL-303242-X ophthalmic suspension
- Where
- United States
- Volunteers
- 356 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects
The purpose of this study is to demonstrate the superior efficacy of Systane® Balance over Preservative-Free 0.9% Saline following 35 days of QID (4 times a day) dosing in treating dry eye subjects with lipid deficiency.
- Trial name
- NCT01967147
- Testing
- Propylene Glycol, 0.6% eye drops, Preservative-free 0.9% Saline solution
- Volunteers
- 279 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by…
- Trial name
- NCT02910713
- Testing
- Intranasal Tear Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Allergan
Blepharitis, Dry Eye Syndrome
Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery
The purpose of this pilot feasibility study is to assess whether treating meibomian gland dysfunction (MGD) prior to cataract surgery helps promote meibomian gland function, visual quality and ocular comfort after cataract…
- Trial name
- NCT01808560
- Testing
- LipiFlow Pre-Treatment, LipiFlow Post-treatment
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- TearScience, Inc.
Dry Eye Syndromes
Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1.
- Trial name
- NCT02013791
- Testing
- Vehicle, Cyclosporine New Ophthalmic Formulation
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Allergan
Sjogren's Syndrome
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
This study will evaluate the safety and tolerability of iscalimab at two dose levels in patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201 (NCT03905525).
- Trial name
- TWINSS Extn (NCT04541589)
- Testing
- Iscalimab
- Where
- 62 sites in United States, Argentina and 21 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.
Dry Eye
Acute Comfort of Lubricant Eye Drops FID 112903
To evaluate the acute comfort and blurring profile between two artificial tears in dry eye patients.
- Trial name
- NCT00673855
- Testing
- Lubricant Eye Drops FID 112903, Optive Lubricant Eye Drops
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alcon Research
Keratoconjunctivitis Sicca
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)
- Trial name
- NCT02845674
- Testing
- OTX-101 0.09%
- Volunteers
- 258 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye
Clinical Trial to Compare the Safety and Efficacy of Nanodrop®
Study design: Phase I-II clinical trial, comparative, non-inferiority with active control, parallel groups, double blind with randomisation.
- Trial name
- PRO-176/I (NCT04111965)
- Testing
- Nanodrop®, Systane Balance
- Where
- 6 sites in Mexico
- Volunteers
- 126 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects…
- Trial name
- NCT05062330
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Eye Syndromes
A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease
The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.
- Trial name
- NCT01135511
- Testing
- CP-690,550 Eye drops, CP-690,550 Eye drops-vehicle, Sodium Hyaluronate
- Where
- 28 sites in Japan, South Korea
- Volunteers
- 285 people
- Sponsor
- Pfizer